Agung Pranoto (2017) The Evidence Base of Vildagliptin for T2DM Patient During Ramadan. In: Proceeding The Quadruple Joint Symposium-2017A. Pusat Diabetes Dan Nutrisi Departemen-SMF Penyakit Dalam Fakultas Kedokteran Universitas Airlangga, Surabaya, pp. 81-88. ISBN 978-602-71520-8-3
![[img]](https://repository.unair.ac.id/style/images/fileicons/text.png) |
Text (Artikel)
The Evidence Base of Vildagliptin for T2DM Patient During Ramadan_compressed.pdf Download (2MB) |
|
Text (Similarity)
The Evidence Base of Vildagliptin for T2DM Patient During Ramadan.pdf Download (2MB) |
|
Text (Peer Review)
peer.pdf Download (1MB) |
Abstract
Dipeptidyl peptidase-4 (DPP-4) inhibitors merupakan obat golongan baru (vildagliptin sitagliptin, saxagliptin, linagliptin, alogliptin), obat yang meningkatkan kontrol glikemik dengan memperbaiki fungsi dari hormone incretin, sehingga pada pengelolaan Diabetes Mellitus (DM), diberi nama dengan "incretin based therapy". Dalam fisiologi normal, usus memberikan respon terhadap asupan makanan dengan melepaskan hormone incretin misal GLP-1 (glucagon like peptide-1) dan GIP (gastric inhibitory polypeptide), yang berefek meningkatkan biosintesis dan sekresi insulin, dan memperlambat waktu pengosongan lambung.
| Item Type: | Book Section | ||||
|---|---|---|---|---|---|
| Uncontrolled Keywords: | Vildagliptin, Patient During Ramadan, T2DM | ||||
| Subjects: | R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC31-1245 Internal medicine |
||||
| Divisions: | 01. Fakultas Kedokteran > Ilmu Penyakit Dalam | ||||
| Creators: |
|
||||
| Depositing User: | arys fk | ||||
| Date Deposited: | 02 Oct 2019 08:15 | ||||
| Last Modified: | 27 Dec 2019 09:47 | ||||
| URI: | http://repository.unair.ac.id/id/eprint/86383 | ||||
| Sosial Share: | |||||
Actions (login required)
 |
View Item |